Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tersolisib · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 Treatment A Fasted | EXPERIMENTAL | Tersolisib administered orally. |
| Group 1 Treatment B High-Fat Meal | EXPERIMENTAL | Tersolisib administered orally. |
| Group 2 Treatment A Fasted | EXPERIMENTAL | Tersolisib administered orally. |
| Group 2 Treatment C Low-Fat Meal | EXPERIMENTAL | Tersolisib administered orally. |
| Name | Type | Description |
|---|---|---|
| Tersolisib | DRUG | Tersolisib administered orally |
| High-fat Meal | OTHER | High-fat Meal |
| Low-fat Meal | OTHER | Low-fat Meal |
Inclusion Criteria: * Are healthy as determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram (ECG), vital sign measurements, or clinical laboratory evaluations. * Normal blood pressure and pulse rate. * Body mass index (BMI) within the ...
Tersolisib is an investigational small molecule being studied in healthy participants. It is currently in Phase 1 clinical development, with an active trial evaluating the effect of food on the drug in healthy volunteers. The drug is not approved for any condition and remains under investigation.
Tersolisib is a small molecule that belongs to the -lisib class of drugs, which target phosphoinositide 3-kinase (PI3K). PI3K is an enzyme involved in cellular signaling pathways. The drug is being studied in healthy participants to assess its pharmacokinetic profile.
Tersolisib is being developed by Eli Lilly and Company, a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol LLY. The company is conducting a Phase 1 clinical trial to evaluate the drug in healthy participants.
Tersolisib is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is designed to study the effect of food on the drug in healthy participants.
Tersolisib is being studied in one active Phase 1 clinical trial with the identifier NCT07662798. The trial, titled 'A Study of Food Effect on Tersolisib (LY4064809) in Healthy Participants,' is enrolling 60 healthy adults in the United States. The study is not currently recruiting participants.